Uzan et al 23. Haddad B, Kayem G, Deis S, Sibai BM. Are perinatal and maternal out- comes different during expectant management of severe preeclampsia in the presence of intrauterine growth restriction? Am J Obstet Gynecol. 2007;196:237. e1–e5. 24. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979–988. 25. Haddad B, Sibai BM. Expectant management in pregnancies with severe pre eclampsia. Semin Perinatol. 2009;33:143–151. 26. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Sibai BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks’ gestation. Am J Obstet Gynecol. 2004;190:1590–1595. 27. Jenkins SM, Head BB, Hauth JC. Severe preeclampsia at ,25 weeks of gestation: maternal and neonatal outcomes. Am J Obstet Gynecol. 2002;186:790–795. 28. Budden A, Wilkinson L, Buksh MJ, McCowan L. Pregnancy outcome in women presenting with pre-eclampsia at less than 25 weeks gestation. Aust N Z J Obstet Gynaecol. 2006;46:407–412. 29. Duley L, Henderson-Smart J, Meher S. Drugs for treatment of very high blood pressure during pregnacy. Cochrane Database Syst Rev. 2006;(3):CD001449. 30. Olsen KS, Beier-Holgersen R. Fetal death following labetalol administra- tion in pre-eclampsia. Acta Obstet Gynecol Scand. 1992;7:145–147. 31. Amorin MMR, Santos LC, Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe pre eclampsia. Am J Obstet Gynecol. 1999;180:1283–1288. 32. Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009;114:669–673. 33. Sibai BM. Diagnosis, prevention and management of eclampsia. Am Coll Obstet Gynecol. 2005;105:402–410. 34. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357:2002–2006. 35. Funai EF, Friedlander Y, Paltiel O, et al. Long-term mortality after preeclampsia. Epidemiology. 2005;16:206–215. 36. Tan LK, de Swiet M. The management of postpartum hypertension. BJOG. 2002;109:733–736. 37. Mostello D, Catlin TK, Roman L, Holcomb WL Jr, Leet T. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol. 2002;187:425–429. Dovepress 38. Royal College of Obstetricians and Gynaecologists. Pre-eclampsia – study group consensus statement. Available from: http://www.rcog. org.uk/womens-health/clinical-guidance/pre-eclampsia-study-group- consensus-statement. Accessed June 8, 2011. 39. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre eclampsia: population based cohort study. BMJ. 2001;323:1213–1217. 40. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367–1391. 41. Gomez O, Martinez JM, Figueras F, et al. Uterine artery Doppler at 11–14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol. 2005;26:490–494. 42. Rizzo G, Capponi A, Cavicchioni O, Vendola M, Arduini D. First trimester uterine Doppler and three-dimensionnal ultrasound placental volume calculation in predicting pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2008;138:147–151. 43. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658. 44. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326. e1–e13. 45. Thilaganathan, Wormald B, Zanardini C, Sheldon J, Ralph E, Papageorghiou AT. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol. 2010;115:1233–1238. 46. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–1798. 47. Sergio F, Maria Clara D, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy. 2006;25: 115–127. 48. Villar J, Abdel-Aleem H, Merialdi M, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006;194:639–649. 49. Maynard SE, Karumanchi SA, Thadhani R. Hypertension and kidney disease in pregnancy. In: Brenner BM, editor. Brenner and Rector’s The Kidney. 8th ed. Philadelphia, PA: WB Saunders; 2007. Vascular Health and Risk Management Publish your work in this journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal Dovepress 474 submit your manuscript | www.dovepress.com Dovepress Vascular Health and Risk Management 2011:7